AeroRx Therapeutics, Inc., a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies ...

Source Reference: Sin DD "RETHINCking COPD -- bronchodilators for symptomatic tobacco-exposed persons with preserved lung function?" N Engl J Med 2022; DOI: 10.1056/NEJMe2210347.

Researchers supported by the National Institutes of Health have found that dual bronchodilators - long-lasting inhalers that relax the airways and make it easier to breathe - do little to help ...

The demand for bronchodilators is growing significantly, owing to the increasing incidence of respiratory disorders. The surging number of smokers is increasing the population with a heightened risk ...

Bronchodilators in Tobacco-Exposed Persons with Symptoms and Preserved Lung Function. New England Journal of Medicine, 2022; DOI: 10.1056/NEJMoa2204752 ...

Bronchodilators Market Size, Share & Trends Analysis Report By Disease (Asthma, COPD), By Route Of Administration (Inhalable, Oral), By Drug Class (Beta-Adrenergic, Anticholinergics), By Region ...

Bronchodilators don’t improve smoking-related respiratory symptoms in people without COPD About 20–40% of adults with COPD symptoms but who aren’t diagnosed with COPD use these types of long ...

Long-Acting Bronchodilators Long-acting bronchodilators are another type of controller medication. They work like rescue inhalers, but the effects last longer, usually about 12 hours.

Review Article Open access Published: 17 July 2014 Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma? David Price, Leonard Fromer, Alan Kaplan, Thys van der ...

Original Article Archive Bronchodilators and Corticosteroids in the Treatment of Obstructive Pulmonary Emphysema Authors: William Franklin, M.D., A. L.